|  |



Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug

Lenacapavir is already approved for treatment of HIV, and is under regulatory review for prevention, but it has a price tag of $42,250. As a result, ...


View article...


Top stories of the last 30 days